格隆汇8月5日丨瑞联新材(688550.SH)在互动平台表示，光刻胶材料因其金属离子含量、杂质控制及水 含量等方面要求更为严格，客户验证周期普遍较长。目前公司储备有多款光刻胶材料产品，部分光刻胶 单体材料已量产，部分产品处于客户验证阶段。 ...

人民财讯8月5日电，瑞联新材(688550)8月5日在互动平台表示，光刻胶材料因其金属离子含量、杂质控 制及水含量等方面要求更为严格，客户验证周期普遍较长。目前公司储备有多款光刻胶材料产品，部分 光刻胶单体材料已量产，部分产品处于客户验证阶段。 ...

Core Viewpoint - The company focuses on innovative pharmaceutical intermediates in its medical business, with growth expected in the first half of 2025 due to adjustments in customer procurement demands and increased volume of certain innovative pharmaceutical intermediates [1] Summary by Categories Company Overview - The company, 瑞联新材 (688550.SH), is primarily engaged in the production of innovative pharmaceutical intermediates [1] Business Growth Factors - Growth in the pharmaceutical segment for the first half of 2025 is attributed to adjustments in customer procurement needs and the further ramp-up of certain innovative pharmaceutical intermediates [1]

8月4日，沪深两融数据显示，瑞联新材上周累计获融资净买入额6694.94万元，居两市第133位，上周融 资买入额2.00亿元，偿还额1.33亿元。 瑞联新材所属概念板块包括：电子化学品、陕西板块、股权转让、沪股通、举牌、融资融券、预盈预 增、机构重仓、创新药、光刻机(胶)、OLED、西部大开发、新材料。 通过天眼查大数据分析，西安瑞联新材料股份有限公司共对外投资了11家企业，参与招投标项目5次， 知识产权方面有商标信息8条，专利信息188条，此外企业还拥有行政许可31个。 来源：金融界 资金流方面，瑞联新材近5日主力资金流入4374.83万元，区间涨幅5.43%；近10日主力资金流出4029.93 万元，区间跌幅2.69%。 天眼查商业履历信息显示，西安瑞联新材料股份有限公司，成立于1999年，位于西安市，是一家以从事 化学原料和化学制品制造业为主的企业。企业注册资本17210.7058万人民币，实缴资本5000.0003万人民 币。公司法定代表人为刘晓春。 ...

Group 1 - The core point of the article highlights the financing activities of RuiLian New Materials, indicating a net selling position in the recent trading days [1] - On August 1, RuiLian New Materials had a financing buy amount of 0.16 billion yuan, ranking 894th in the market, with a financing repayment amount of 0.17 billion yuan, resulting in a net sell of 1.459 million yuan [1] - Over the last three trading days, the financing buy amounts were 0.51 billion yuan, 0.22 billion yuan, and 0.16 billion yuan respectively [1] Group 2 - In terms of securities lending, on the same day, there were no shares sold or net sold, indicating no activity in this area [1]

Market Performance - The electronic chemicals sector declined by 1.53% on July 31, with Rongda Photoelectric leading the drop [1] - The Shanghai Composite Index closed at 3573.21, down 1.18%, while the Shenzhen Component Index closed at 11009.77, down 1.73% [1] Stock Performance - Siquan New Materials (301489) saw a significant increase of 20.00%, closing at 103.66 with a trading volume of 66,300 shares and a transaction value of 667 million [1] - Tiancheng Technology (688603) increased by 1.97%, closing at 65.26 with a trading volume of 98,000 shares and a transaction value of 659 million [1] - Other notable performances include Tongyu New Materials (301630) up by 0.91%, Guanghua Technology (002741) up by 0.61%, and Zhongshi Technology (300684) up by 0.50% [1] Capital Flow - The electronic chemicals sector experienced a net outflow of 795 million from institutional investors, while retail investors saw a net inflow of 851 million [3] - Speculative funds had a net outflow of 56.71 million [3]

Group 1 - RuiLian New Materials plans to terminate the raw material project of Weinan RuiLian Pharmaceutical due to uncertainties in the construction timeline of the second phase [1] - HaiDa Group reported a net profit of 2.639 billion yuan for the first half of 2025, a year-on-year increase of 24.16% [1] Group 2 - JinCheng Pharmaceutical's subsidiary received the CEP certificate for Oseltamivir phosphate chemical raw material from the European Medicines Agency [2] - WenFeng Co. announced that 124 million shares held by shareholder Zheng SuZhen will be judicially auctioned [3] Group 3 - ShanJin International plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [5] - XiDian Pharmaceutical's shareholders plan to reduce their holdings by up to 3% of the company's total shares [7] Group 4 - ZhongTung High-Tech's subsidiary intends to purchase assets from Wukuang Tungsten Industry for 135 million yuan [9] - ZhongTung High-Tech's subsidiary plans to implement a 1.4 billion micro-drill intelligent manufacturing project with an estimated total investment of 178 million yuan [10] Group 5 - TianYi Co. has been selected as the first candidate for two procurement projects by China Mobile, with a total share of 160% [11] - GuangKu Technology is planning a major asset restructuring and has suspended trading of its stock [13] Group 6 - FaShiLong's controlling shareholder plans to transfer part of its shares, with the stock resuming trading [14] - TaiGe Pharmaceutical's shareholder plans to reduce holdings by up to 3 million shares [15] Group 7 - DaLian ShengYa's controlling shareholder is set to change, with the stock resuming trading [16] - JuRan Smart Home announced the passing of its actual controller and CEO, Wang LinPeng [18] Group 8 - JingQuanHua's shareholder plans to reduce holdings by up to 1% of the company's total shares [19] - JiangTe Electric's control change has progressed, with the stock resuming trading [21] Group 9 - AiWei Electronics plans to issue convertible bonds to raise up to 1.901 billion yuan for various projects [22] - ShangWei New Materials stated that its stock price has significantly deviated from its current fundamentals [22] Group 10 - JingHe Integrated plans to invest 1.195 billion yuan in Anhui Jingmei to support its layout in the photomask industry [23]

Core Viewpoint - Xi'an Ruilian New Materials Co., Ltd. is undergoing a board of directors re-election process, with the fourth board set to consist of 5 non-independent directors, 3 independent directors, and 1 employee director, aiming to ensure stable and compliant operations [1][2]. Board Election Summary - The third board of directors held a meeting on July 28, 2025, to approve the election of the fourth board of directors, which will include modifications to the company's articles of association to eliminate the supervisory board and add an employee director [1][2]. - The election will take place during the third extraordinary general meeting of shareholders on August 13, 2025, using a cumulative voting system for both non-independent and independent directors [2][3]. Candidate Information - Non-independent director candidates include Liu Xiaochun, Wang Wenli, Ji Kaishi, Yu Xiangjin, and Ding Shan, all of whom have agreed to the nomination and meet the qualifications required by law [2][5]. - Independent director candidates are Xiao Baoqiang, Yu Hong, and Chen Xi, with qualifications verified by the Shanghai Stock Exchange [2][11]. Compliance and Qualifications - All nominated candidates have been confirmed to meet the legal requirements for directorship, with no records of penalties or disqualifications from regulatory bodies [2][3][11]. - The candidates possess relevant educational backgrounds and professional experiences that align with the responsibilities of their respective roles [5][11][12].

Core Viewpoint - The company has decided to terminate the raw material drug project due to uncertainties in the project's second phase and aims to find more profitable projects for the remaining raised funds [2][8][10]. Fundraising Overview - The company raised a total of RMB 1,995.79 million by issuing 17.55 million shares at RMB 113.72 per share [2][3]. - As of June 30, 2025, the cumulative investment in the raw material drug project was RMB 178.70 million, with pending payments of RMB 6.11 million and remaining funds of RMB 215.69 million [2][6]. Investment Projects - The company has several fundraising investment projects, including: - OLED and other functional materials production project with a total investment of RMB 300.00 million [4]. - High-end liquid crystal display materials production project with a total investment of RMB 310.00 million [4]. - Resource harmless treatment project with a total investment of RMB 37.21 million [4]. - Research and testing center project with an investment of RMB 170.00 million [4]. - Working capital supplement of RMB 260.00 million [4]. Termination of Investment Project - The raw material drug project was intended to expand the company's pharmaceutical CDMO business, with a total investment of RMB 423.00 million, using RMB 369.00 million of excess raised funds [6][8]. - The first phase of the project has been completed, but the second phase has not started due to uncertainties in product planning and regulatory approval processes [7][8]. Impact of Termination - The decision to terminate the raw material drug project is based on current industry trends and aims to optimize the use of resources and funds, ensuring high-quality project implementation [8][10]. - The termination is not expected to adversely affect the company's normal operations and aligns with its long-term development strategy [8][10]. Review Procedures - The board and supervisory committee approved the termination of the investment project, which will be submitted for shareholder approval [10][11]. - The supervisory committee and the sponsor institution have expressed their agreement with the decision, confirming that it complies with relevant regulations and does not harm shareholder interests [10][11].

Core Viewpoint - Xi'an Ruilian New Materials Co., Ltd. has decided to abolish its supervisory board and amend its articles of association, transferring the supervisory functions to the audit committee of the board of directors [1][2]. Summary by Sections Cancellation of Supervisory Board and Amendment of Articles - The company will no longer have a supervisory board, with its powers being transferred to the audit committee of the board of directors [1]. - The decision was made in accordance with the revised Company Law of the People's Republic of China and related regulations [1]. - The company held a board meeting on July 28, 2025, to approve the proposal to amend the articles of association and abolish the supervisory board, pending approval from the shareholders' meeting [1]. Amendments to Articles of Association - The articles of association have been revised to remove references to the supervisory board and replace them with the audit committee [2]. - The amendments include changes to various clauses, such as the definition of the shareholders' meeting, which is now referred to as the "shareholders' assembly" [2]. - The company’s registered capital has been updated from RMB 172.107058 million to RMB 173.575305 million [5][6]. Responsibilities and Compliance - Until the shareholders' meeting approves the cancellation of the supervisory board, the existing supervisory board will continue to fulfill its supervisory duties in accordance with relevant laws and regulations [2]. - The company emphasizes the importance of maintaining compliance with the Company Law, Securities Law, and corporate governance standards during this transition [2].